GSA Capital Partners’s Juniper Pharmaceuticals, Inc. Common Stock JNP Stock Holding History

GSA Capital Partners’s Portfolio JNP Stock Details JNP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q1	–	Sell	-20,792	Closed	-$116K	–	2149
2016 Q4	$116K	Sell	20,792 -2,600	-11%	-$14.3K	0.01%	1670
2016 Q3	$130K	Sell	23,392 -10,514	-31%	-$69.5K	0.01%	1670
2016 Q2	$238K	Sell	33,906 -95,270	-74%	-$671K	0.01%	1496
2016 Q1	$854K	Sell	129,176 -44,888	-26%	-$330K	0.05%	642
2015 Q4	$1.79M	Buy	174,064 +73,500	+73%	+$852K	0.09%	302
2015 Q3	$1.19M	Buy	100,564 +53,308	+113%	+$589K	0.06%	535
2015 Q2	$432K	Sell	47,256 -5,000	-10%	-$37.8K	0.02%	1440
2015 Q1	$325K	Buy	52,256 +4,635	+10%	+$28.7K	0.01%	1674
2014 Q4	$267K	Sell	47,621 -5,000	-10%	-$29.1K	0.02%	1330
2014 Q3	$310K	Sell	52,621 -10,861	-17%	-$66.2K	0.02%	1246
2014 Q2	$435K	Sell	63,482 -4,900	-7%	-$32.8K	0.02%	1226
2014 Q1	$494K	Hold	68,382	–	–	0.04%	787
2013 Q4	$452K	Hold	68,382	–	–	0.04%	921
2013 Q3	$497K	Buy	+68,382	New	+$460K	0.04%	802

Other funds holding JNP

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Heartland Advisors Milwaukee, Wisconsin $1.96B AUM 28.26% 1-Year Est. Return

JAM

JW Asset Management Miami Beach, Florida $244M AUM 71.51% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

KAM

Krensavage Asset Management New York $256M AUM 69.63% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Algert Global San Francisco, California $6.65B AUM 53.68% 1-Year Est. Return

AIC

AWM Investment Company New York $903M AUM 163.47% 1-Year Est. Return

GSA Capital Partners's JNP Position: Q1 2017 in Review

GSA Capital Partners sold out of Juniper Pharmaceuticals, Inc. Common Stock (JNP) in Q1 2017, closing a stake of 20,792 shares — an estimated $116K sold.

GSA Capital Partners first reported a position in JNP in Q3 2013 and held it in 14 quarters. The position peaked at $1.79M in Q4 2015. 38 funds tracked by Wall St. Rank hold JNP as of Q1 2017.

GSA Capital Partners reported no remaining Juniper Pharmaceuticals, Inc. Common Stock position as of Q1 2017 after selling out during the quarter.
GSA Capital Partners sold 20,792 Juniper Pharmaceuticals, Inc. Common Stock shares in Q1 2017, an estimated $116K.
GSA Capital Partners first reported a position in Juniper Pharmaceuticals, Inc. Common Stock in Q3 2013 and held it in 14 quarters.
GSA Capital Partners's Juniper Pharmaceuticals, Inc. Common Stock position peaked at $1.79M in Q4 2015.
38 funds tracked by Wall St. Rank held Juniper Pharmaceuticals, Inc. Common Stock as of Q1 2017.

Based on GSA Capital Partners's 13F filing for Q1 2017, filed 15 May 2017.